When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...

You deposit a lump sum or contribute monthly and acquire your very own slice of the world's starriest companies.

On September 25, 2024, BioAge went public with considerable fanfare, pricing 11 million shares at $18 per share, with renowned Wall Street banks Goldman Sachs, Morgan Stanley, Jefferies and Citigroup ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

The lawsuit was brought against the FDA after the agency declared an end to the shortage that allowed pharmacies to sell compound versions of the popular weight loss drugs, but Eli Lilly said it ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

The state has spent more than $690 million so far establishing the LEAP Research and Innovation District. Outgoing economic ...

Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome could affect its business and that the FDA does not adequately represent its ...

Versant Capital Management Inc increased its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 19.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,167 shares of the ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...